

Message

From: Kraft, Andrew [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=4A94A4F199B247778ABB02285A51B927-KRAFT, ANDREW]
Sent: 12/3/2014 2:23:57 PM
To: Makris, Susan [Makris.Susan@epa.gov]; Glenn, Barbara [Glenn.Barbara@epa.gov]
Subject: RE: Dev-Repro evidence integration pieces

Cool beans.

From: Makris, Susan
Sent: Wednesday, December 03, 2014 9:21 AM
To: Kraft, Andrew; Glenn, Barbara
Subject: RE: Dev-Repro evidence integration pieces

Hi Andrew, I'm not sure I have the most recent update of the exposure quality table. And I recognize that the dev/repro exposure quality table needs to be revised and updated. We will probably need to coordinate further across noncancer quality tables (and approaches). Regarding non-inhalations studies... I think I only have MOA studies in the quality table, but I might be mistaken. And only inhalation studies are used in the evidence. I will have to check on that. Even with all that being said, I still think we can still have a fruitful conversation today as we work through the process. Sue

From: Kraft, Andrew
Sent: Wednesday, December 03, 2014 8:22 AM
To: Makris, Susan; Glenn, Barbara
Subject: RE: Dev-Repro evidence integration pieces

Hi Sue,

I just gave a quick skim of your quality table, and I noticed a couple things I am guessing we need to make sure are consistent across the toxicology sections.

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Looking forward to seeing you guys pull it all together (fun section!).

-Andrew

From: Makris, Susan
Sent: Tuesday, December 02, 2014 7:42 PM
To: Glenn, Barbara
Cc: Kraft, Andrew
Subject: Dev-Repro evidence integration pieces

I have attached several files. One is the table with animal evidence, in which you will need to update the human evidence. I did not try to integrate the details of the mechanistic information into the table. Instead I clipped it out of the document and put it in a separate file for consideration. And I am attaching what I think is the last version of the study quality assessment for the dev-repro studies. There are a couple more studies that I have not yet incorporated into the assessment, but I don't think they will make a significant difference in the big picture. Sue

Susan Makris
USEPA/ORD/NCEA (8623P)
1200 Pennsylvania Ave., NW
Washington, DC 20460
Office: 703-347-8522
Fax: 703-347-8692
makris.susan@epa.gov

Courier address:

Two Potomac Yard (North Building)
2733 S. Crystal Dr. (Rm N7712)
Arlington, VA 22202